Gilead Sciences . A few weeks ago, we raised our fair value estimate for Gilead to $71 per share, based on positive clinical trial results and a lower cost of equity assumption.
http://news.morningstar.com/articlenet/article.aspx?id=606493&pgid=rss
http://news.morningstar.com/articlenet/article.aspx?id=606493&pgid=rss
No comments:
Post a Comment